KBY Biotech Indexv0.0.34
Search
← Pipeline|Tirarapivir

Tirarapivir

Approved
UTH-6025
By United Therapeutics
Source: Trial-derived·Trials: 4
Modality
siRNA
MOA
CD47i
Target
SGLT2
Pathway
Complement
Parkinson'sPAH
Development Pipeline
Preclinical
~Jun 2011
→ ~Sep 2012
Phase 1
~Dec 2012
→ ~Mar 2014
Phase 2
~Jun 2014
→ ~Sep 2015
Phase 3
~Dec 2015
→ ~Mar 2017
NDA/BLA
~Jun 2017
→ ~Sep 2018
Approved
Dec 2018
→ Sep 2030
ApprovedCurrent
NCT03528796
1,896 pts·Parkinson's
2018-12→2026-05·Terminated
NCT03837934
2,375 pts·Parkinson's
2020-11→2027-11·Active
NCT03830158
1,255 pts·Parkinson's
2025-08→2030-09·Recruiting
+1 more trial
8,394 total pts2 indications
CompletedCurrentUpcoming
Catalysts (4)
2026-05-172mo awayPh3 Readout· Parkinson's
2027-11-111.6y awayPh3 Readout· Parkinson's
2028-03-242.0y awayPh3 Readout· PAH
2030-09-134.5y awayPh3 Readout· Parkinson's
Trial Timeline
Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q4
Approved
Termina…
Approved
Active
Approved
Active
Approved
Recruit…
Catalysts
Ph3 Readout
2026-05-17 · 2mo away
Parkinson's
Ph3 Readout
2027-11-11 · 1.6y away
Parkinson's
Ph3 Readout
2028-03-24 · 2.0y away
PAH
Ph3 Readout
2030-09-13 · 4.5y away
Parkinson's
RecruitingActiveTerminated|StartCompletionToday
Trials (4)
NCTPhaseIndicationStatusNEP
NCT03528796ApprovedParkinson'sTerminated1896LiverFat
NCT03837934ApprovedParkinson'sActive2375BodyWt
NCT03830158ApprovedParkinson'sRecruiting1255UPCR
NCT07278178ApprovedPAHActive2868DAS28
Competitors (10)
DrugCompanyPhaseTargetMOA
NirarelsinJohnson & JohnsonPhase 2PRMT5CD47i
CevizanubrutinibJohnson & JohnsonPreclinicalFcRnCD47i
RHH-7558RochePhase 1SGLT2Anti-Tau
CeviglumideRocheNDA/BLAB7-H3CD47i
TiramavacamtenRochePreclinicalSGLT2PI3Ki
NVS-1475NovartisPhase 2MeninCD47i
AZN-6294AstraZenecaPhase 2/3APOC3CD47i
RimatenlimabNovo NordiskPhase 2/3SGLT2PI3Ki
ZenonesiranGSKPreclinicalDLL3CD47i
DSN-7360Daiichi SankyoApprovedSGLT2BiTE